Pictured above, Steve Ewald, General Counsel for Medpace, accepts the James A. Wuenker Growth award from Markiea Carter, Kimm Lauterbach and George Vincent at the REDI Cincinnati Annual Meeting.
Through our commitment to expanding with 1,500 new jobs and $150M in capital investment, Medpace is proud to have earned a James A. Wuenker Growth Award from REDI Cincinnati for our continued unprecedented growth in the Cincinnati Region.
REDI Cincinnati recognized four local companies with James A. Wuenker Growth Awards at its annual meeting on Tuesday, March 7. Medpace, along with three other local companies, received recognition for helping the Cincinnati region reach new heights through investments made during the 2022 calendar year.
Named in honor of renowned economic developer James A. Wuenker, who helped shape the future of the Cincinnati region through his efforts, the Growth Awards are annually conferred to companies whose projects announced in the previous year significantly enhanced the economic strength of the Cincinnati region.
“The collective impact of Emerge Manufacturing, Enable Injections, Medpace and Thermo Fisher Scientific cannot be overstated,” said Kimm Lauterbach, REDI Cincinnati president and CEO. “These four projects account for 2,057 new jobs and more than $340 million in capital investment within the Cincinnati region, and each provides significant contributions to our thriving business climate. The decisions of these companies to grow their businesses here are further proof of a vibrant $171 billion regional economy with an established business ecosystem in place for them to flourish. Thank you to each of the four companies for choosing the Cincinnati region.”
In December 2022, Ohio Lieutenant Governor Jon Husted, Pureval, JobsOhio president and CEO J.P. Nauseef and Lauterbach joined Medpace’s CEO and president of the board August Troendle and general counsel Steve Ewald at the company’s Madisonville headquarters for the announcement of a major expansion that included the creation of 1,500 new jobs with $90 million in associated payroll.
The significant job growth is accompanied by a commitment to invest $150 million to expand operations and office capacity through the addition of 250,000 sq. ft. of office space and 1,000 new parking stalls at its headquarters. The clinical contract research organization will increase employment across a wide variety of disciplines, including a heavy focus on STEM talent with physicians, lab technicians, clinical research associates, data analysts, financial analysts, software engineers, and more.
Medpace’s 1,500-job commitment is the second largest in REDI Cincinnati’s history, and the largest project for the City of Cincinnati in REDI Cincinnati’s history.
“Medpace is excited to continue to expand and grow our Clinical Research Campus in Cincinnati and we appreciate the recognition and support from the City of Cincinnati and REDI on this project,” said Jesse Geiger, president, Medpace. “We are looking forward to kicking off the project and adding substantially to our employee base in Cincinnati. Through the meaningful work we do to advance new and better medical treatments, we are able to offer challenging and rewarding roles for a broad range of positions – from the highly technical and specialized to broader business roles.”
For more details on the James A. Wuenker Growth Awards, access the entire press release below:
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,200 people across 40 countries.